Get notified when RGEN files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Asset Impairment (new) — Recorded a $41.2 million impairment charge on developed-technology intangible assets related to an intellectual property license agreement.
- Material Weakness (improved) — Revenue-recognition material weakness remediated; IT and inventory/close weaknesses remain with expanded remediation plans.
- Disclosure Controls Not Effective (new) — Filing states that management concluded the company's disclosure controls and procedures were not effective. The same conclusion appeared in the baseline filing.
Repligen swings to $38.4M net loss on $41.2M impairment; closes $1.9B BioLife deal
Filed October 30, 2026 · Period ending September 30, 2026 · Compared to 10-Q Nov 4, 2025 · ~1 min read
Key Changes
-
high
Net loss of $38.4M ($0.68/share) vs. $14.9M profit a year ago, driven by a $41.2M intangible impairment and a $13.7M loss on the Polymem sale.
MD&A: Results verify on EDGAR → -
high
Completed $1.9B acquisition of BioLife Solutions on Oct 6, funded with 7.2M shares and $564M cash; integration and market-assumption risks added.
MD&A: BioLife verify on EDGAR → -
high
Post-quarter, entered agreements to issue $1.0B of 0.25% convertible notes due 2031, exchanging $456.8M of 2028 notes and raising $458.6M cash; $120M earmarked for share repurchases.
Subsequent Events verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (FUL 10-Q) is open in full — no account needed.
Partner
Trade RGEN commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Nov 2, 2026 · How we verify